Vanda Pharmaceuticals (VNDA) Receivables - Other (2011 - 2012)

Vanda Pharmaceuticals (VNDA) reported Receivables - Other of $21000.0 for Q3 2012, down 19.23% sequentially from $26000.0 in Q2 2012.

Vanda Pharmaceuticals (VNDA) Receivables - Other (2011 - 2012) Analysis & Trends

Vanda Pharmaceuticals (VNDA) has 2 years of Receivables - Other data on file, last reported at $21000.0 in Q3 2012.

For the quarter ending Q3 2012, Receivables - Other changed N/A year-over-year to $21000.0; the trailing twelve-month figure through Sep 2012 stood at $21000.0 (changed N/A YoY), and the FY2011 full-year result was $116000.0, changed N/A from the prior year.
Receivables - Other fell to $21000.0 in Q3 2012, from $26000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $116000.0 in Q4 2011 to a low of $21000.0 in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Vanda Pharmaceuticals	318.71 Mn	116.40 Mn	48.56 Mn

Download Data